Lack of nucleophosmin mutation in patients with myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

References

• Borer R A, Lehner C E, Eppenberger H M, Nigg E A. Major nuclear proteins shuttle between nucleus and cytoplasm. Cell 1989; 56: 379–390
   PubMed Web of Science ®Google Scholar
• Cordell J L, Pulford K AF, Bigerna B, Roncador G, Banham A, Colombo E, et al. Detection of normal and chimeric nucleophosmin in human cells. Blood 1999; 93: 632–642
   PubMed Web of Science ®Google Scholar
• Dumbar T S, Gentry G, Olson M O. Interaction of nuclear phosphoprotein B23 with nucleic acid. Biochemistry 1989; 79: 428–437
   Google Scholar
• Colombo E, Marine J C, Danovi D, Falini B, Pelicci P G. Nucleophosmin regulates the stability and transcriptional activity of p53. Nat Cell Biol 2002; 4: 529–533
   PubMed Web of Science ®Google Scholar
• Itahana K, Bhat K P, Jin A, Itahana Y, Hawke D, Kobayashi R, et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003; 12: 1151–1164
   PubMed Web of Science ®Google Scholar
• Kurki S, Peltonen K, Latonen L, Kiviharju T M, Ojala P M, Meek D, et al. Nucleolar protein NPM interacts with HDM2 and protects tumor suppressor protein p53 from HDM2-mediated degradation. Cancer Cell 2004; 5: 465–475
   PubMed Web of Science ®Google Scholar
• Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005; 352: 254–266
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106: 2854–2861
   PubMed Web of Science ®Google Scholar
• Boissel N, Renneville A, Biggio V, Philippe N, Thomas X, Cayuela J M, et al. Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. Blood 2005; 106: 3618–3620
   PubMed Web of Science ®Google Scholar
• Döhner K, Schlenk R F, Habdank M, Scholl C, Rücker F G, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005; 106: 3740–3746
   PubMed Web of Science ®Google Scholar
• Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli M F, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733–3739
   PubMed Web of Science ®Google Scholar
• Verhaak R GW, Goudswaard C S, van Putten W, Bijl M A, Sanders M A, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005; 106: 3747–3754
   PubMed Web of Science ®Google Scholar
• Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006; 107: 4011–4020
   PubMed Web of Science ®Google Scholar
• Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 473: 147–153
   Web of Science ®Google Scholar
• Solé F, Espinet B, Sanz G F, Cervera J, Calasanz M J, Luno E, et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Br J Haematol 2000; 108: 346–356
   PubMed Web of Science ®Google Scholar
• Xie D, Hofmann W K, Mori N, Miller C W, Hoelzer D, Koeffler H P. Allelotype analysis of the myelodysplastic syndrome. Leukemia 2000; 14: 805–810
   PubMed Web of Science ®Google Scholar
• Horrigan S K, Arbieva Z H, Xie H Y, Kravarusic J, Fulton N C, Naik H, et al. Delineation of a minimal interval and identification of 9 candidates for a tumor suppressor gene in malignant myeloid disorders on 5q31. Blood 2000; 95: 2372–2377
   PubMed Web of Science ®Google Scholar
• Berger R, Busson M, Baranger L, Helias C, Lessard M, Dastugue N, et al. Loss of the NPM1 gene in myeloid disorders with chromosome 5 rearrangements. Leukemia 2006; 20: 319–321
   PubMed Web of Science ®Google Scholar
• Nevill T J, Fung H C, Shepherd J D, Horsman D E, Nantel S H, Klingemann H G, et al. Cytogenetic abnormalities in primary myelodysplastic syndrome are highly predictive of outcome after allogeneic bone marrow transplantation. Blood 1998; 92: 1910–1917
   PubMed Web of Science ®Google Scholar
• Caudill J SC, Sternberg A J, Li C-Y, Teferri A, Lasho T L, Steensma D P. C-terminal nucleophosmin mutations are uncommon in chronic myeloid disorders. Br J Haematol 2006; 133: 638–641
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang M, Yang L, Xiao Z. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leukemia Res 2007; 31: 109–111
   PubMed Web of Science ®Google Scholar
• Pasqualucci L, Liso A, Martelli M P, Bolli N, Pacini R, Tabarrini A, et al. Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classification. Blood 2006; 108: 4146–4155
   PubMed Web of Science ®Google Scholar
• Falini B, Nicoletti I, Martelli M F, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007; 107: 874–885
   Google Scholar
• Jaffe E, Harris E, Stein N, Vardiman J. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues. IARC, LyonFrance 2001
   Google Scholar